GSA Capital Partners’s Immunovant IMVT Stock Holding History

GSA Capital Partners’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.81M	Buy	72,820 +28,680	+65%	+$743K	0.11%	196
2025 Q4	$1.12M	Buy	44,140 +16,992	+63%	+$379K	0.1%	302
2025 Q3	$438K	Buy	+27,148	New	+$440K	0.04%	941
2024 Q4	–	Sell	-24,634	Closed	-$702K	–	1795
2024 Q3	$702K	Buy	24,634 +9,810	+66%	+$289K	0.05%	686
2024 Q2	$391K	Buy	+14,824	New	+$422K	0.03%	1122
2024 Q1	–	Sell	-8,760	Closed	-$369K	–	1788
2023 Q4	$369K	Buy	+8,760	New	+$322K	0.03%	1000
2023 Q3	–	Sell	-32,736	Closed	-$621K	–	1687
2023 Q2	$621K	Buy	+32,736	New	+$610K	0.06%	606
2022 Q4	–	Sell	-95,146	Closed	-$531K	–	1655
2022 Q3	$531K	Buy	95,146 +55,329	+139%	+$270K	0.07%	523
2022 Q2	$155K	Buy	+39,817	New	+$172K	0.02%	1132
2022 Q1	–	Sell	-40,654	Closed	-$346K	–	1597
2021 Q4	$346K	Sell	40,654 -40,516	-50%	-$334K	0.04%	845
2021 Q3	$705K	Buy	+81,170	New	+$732K	0.07%	494
2021 Q1	–	Sell	-5,175	Closed	-$239K	–	1280
2020 Q4	$239K	Buy	+5,175	New	+$239K	0.04%	877

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GSA Capital Partners's IMVT Position: Q1 2026 in Review

GSA Capital Partners increased its Immunovant (IMVT) stake by 65% in Q1 2026, buying an estimated $743K and bringing the position to 72,820 shares worth $1.81M. The position accounts for 0.11% of the portfolio, ranked #196.

GSA Capital Partners first reported a position in IMVT in Q4 2020 and has held it in 12 quarters since. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

GSA Capital Partners held 72,820 shares of Immunovant worth $1.81M as of Q1 2026.
GSA Capital Partners bought 28,680 Immunovant shares in Q1 2026, an estimated $743K.
Immunovant made up 0.11% of GSA Capital Partners's portfolio in Q1 2026, its #196 holding.
GSA Capital Partners first reported a position in Immunovant in Q4 2020 and has held it in 12 quarters since.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.